NTRA
NateraBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The primary-source earnings package supports a still-positive post-print read: revenue growth stayed near 39%, guidance moved higher, gross margin improved, oncology volume remained very strong, and cash generation stayed positive. Secondary post-print coverage on May 8, 2026 showed multiple target increases, including Evercore to $270, Baird to $265, and JPMorgan to $265, which is directionally consistent with a favorable earnings revision signal.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.2.
What can break
2026 guidance calls for R&D of $800M-$900M, up from the prior range, reflecting accelerated clinical-trial and product investment that could pressure near-term profitability even if it supports long-run platform value [#8-K-2026-05-07].
Momentum
87
Value
48
Sentiment
36
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $245.00 · Bull $285.00 · Bear $185.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $283.10
Why
Momentum87 · Δ7d +2.2
Value48 · Δ7d 0.0
Sentiment36 · Δ7d -3.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
26% active weight
Current posture
7d trendFlat
Δ7d
+2.2
Δ21d
+1.8
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.1
Sentiment
36
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.4
Δ21d
-4.8
Why this grade
Composite grade B. Momentum 86.7 / Value 48.4 / Sentiment 36.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$37.61B
Beta
1.63
Shares Out
143.22M
P/E (TTM) · Derived
-172.5
P/S (TTM)
15.61
P/FCF (TTM)
353.07
Rev YoY
+38.8%
EPS YoY
+21.1%
Gross Margin
+64.8%
Op Margin
-16.6%
Net Debt
-$861.76M
Current Ratio
2.96
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology